Previous Article | Next Article 
Journal of Clinical Microbiology, December 1999, p. 4086-4092, Vol. 37, No. 12
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Scored Antibody Reactivity Determined by
Immunoblotting Shows an Association between Clinical Manifestations and
Presence of Borrelia burgdorferi sensu stricto, B. garinii, B. afzelii, and B. Valaisiana
in Humans
Karine
Ryffel,1
Olivier
Péter,1,*
Bernard
Rutti,2
André
Suard,3 and
Eric
Dayer1
Maladies Infectieuses et Immunologie,
Institut Central des Hôpitaux Valaisans, 1950 Sion-CH,1 Institut de Zoologie,
Université de Neuchâtel, 2007 Neuchâtel-CH,2 and Rue du Bourg 1,
1870 Monthey,3 Switzerland
Received 1 March 1999/Returned for modification 3 May 1999/Accepted 16 August 1999
 |
ABSTRACT |
An immunoglobulin G immunoblot was developed with antigenic
extracts of Borrelia burgdorferi sensu stricto,
B. garinii, B. afzelii, and B. valaisiana genospecies and was reacted with sera from patients
with neuroborreliosis, acrodermatitis, and Lyme arthritis. A detailed
analysis of the reactivities of the protein bands was performed, and a
two-step scoring procedure was selected to determine the preferential
reactivity of sera to one particular genospecies. The discriminative
potential of 5 proteins (12-kDa, 16-kDa, 18-kDa, OspA, and 66-kDa
proteins) was used as a rapid first-step scoring method, followed by
scoring of 14 additional protein bands if necessary. The advantage of
this procedure is the low percentage of serum samples with inconclusive
results for one of the four species (10% for patients with
neuroborreliosis, 6% for patients with acrodermatitis chronica
atrophicans, and 6% for patients with Lyme arthritis). Among 31 serum
samples from patients with neuroborreliosis, 16 were more reactive to
B. garinii, 7 were more reactive to B. afzelii,
3 were more reactive to B. valaisiana, and 2 were more
reactive to B. burgdorferi sensu stricto. Of 31 serum
samples from patients with acrodermatitis, 26 showed a higher level of
reactivity to B. afzelii. Of 34 serum samples from patients
with Lyme arthritis, 21 were more reactive to B. burgdorferi sensu stricto, 10 were more reactive to B. afzelii, and 1 was more reactive to B. valaisiana.
Our results suggest an organotropism of Borrelia species
and provide some evidence of a pathogenic potential of B. valaisiana in humans.
 |
INTRODUCTION |
Lyme borreliosis (LB) is a
tick-borne multistage disease caused by the spirochetal bacterium
Borrelia burgdorferi sensu lato. B. burgdorferi
sensu lato is divided into several species on the basis of phenotypic
and genotypic characteristics (35). In Europe, five species
of B. burgdorferi sensu lato have been isolated from Ixodes ricinus: B. burgdorferi sensu stricto,
B. garinii, B. afzelii (4, 9), group
VS116, which has been classified as B. valaisiana novel
species (44), and B. lusitaniae (24).
It appears that the geographic distributions of these species are not
uniform, even within neighborhoods (34). However, in Western
Europe and Switzerland, B. garinii is more frequently isolated, followed by B. afzelii, B. burgdorferi
sensu stricto, and B. valaisiana, in that order
(39). In Scandinavia and The Netherlands, B. afzelii is probably the most common Borrelia (36, 42), followed by B. valaisiana, B. burgdorferi sensu stricto, and B. garinii. In Ireland,
B. valaisiana is described as the most prevalent
genospecies, followed by B. garinii, B. burgdorferi sensu stricto, and B. afzelii
(23). B. lusitaniae was first isolated from
I. ricinus in Portugal and was subsequently isolated from
ticks in other European countries (24).
After a person is bitten by an infected tick, the spirochetes undergo a
hematogenous dissemination and can be found in many of the major organ
systems. The first stage and hallmark of LB is a distinctive skin rash,
erythema migrans (EM), that frequently appears at the site of the tick
bite (40). Days to months after the tick bite, the disease
may progress toward secondary and tertiary stages. In some patients,
chronic diseases may develop. These may affect the skin, such as
acrodermatitis chronica atrophicans (ACA), a clinical manifestation
primarily observed in Europe, and possibly affect joints with
arthritis, which is more common in the United States (40).
In Europe, neurological symptoms appear in 30% of untreated patients
and musculoskeletal symptoms appear in 20% of patients (1).
These observations have suggested that clinical outcome could depend on
infection with strains of different genospecies. Neurological symptoms
are thought to be mainly caused by B. garinii, while
B. afzelii is often associated with ACA and B. burgdorferi sensu stricto is often associated with Lyme arthritis
(3, 13, 32, 42). However, controversial reports described a
good match between the distribution of B. burgdorferi: sensu
lato in ticks and in patients from the same area (14) or an
organotropism linked to strain-specific characteristics, not to
genotypes (45). Furthermore, the pathogenic potential of
B. valaisiana was suggested among patients with EM by using PCR (37), but there is no previous indication of an
association of B. valaisiana with chronic clinical symptoms.
Immunoblotting is unanimously reported to be a confirmatory test for
LB. One of the factors affecting the performance of this assay is the
polymorphism of Borrelia antigens which is evident among
species and intraspecies. Norman et al. (30) found that the
preferential reactivity to genospecies is not absolute and that
regional variations in the reactivity to the genospecies strains may
occur. The purpose of the current study was to compare the
immunoglobulin G (IgG) immunoblots of four different
Borrelia genospecies present in Switzerland (34).
Therefore, we tested sera from patients living in Switzerland. In order
to decrease the percentage of serum samples with an inconclusive
predominance of one of the four species, we modified the scoring method
described by Péter et al. (32). The preferential
reactivity of sera led us to confirm the association between some
manifestations of LB and the species of B. burgdorferi sensu lato.
(This research is part of the Ph.D dissertation of K. Ryffel.)
 |
MATERIALS AND METHODS |
Study samples.
Serum samples from Swiss patients with a
clinical diagnosis of late LB and a positive screening test confirmed
by immunoblotting were collected among sera referred for testing by a
confirmatory diagnostic procedure. The sera were from 31 patients with
neuroborreliosis, 31 patients with ACA, and 34 patients with Lyme
arthritis. Sera from patients with several symptoms of LB were
excluded. Among serum samples from patients with neuroborreliosis, all
were confirmed to be positive by intrathecal antibody synthesis. The
index of intrathecal antibody production was calculated as follows:
IgG-specific titer in cerebrospinal fluid (CSF)/IgG-specific titer in
serum divided by albumin concentration in CSF/albumin concentration in
serum (negative result, index below 2.0).
In order to establish the persistence of the reactivity to the
infecting species after antibiotic therapy, parallel serum samples from
patients were tested. Patients with neuroborreliosis (n = 2), ACA (n = 6), and arthritis (n = 1) were selected. The first serum samples were taken during the
first clinical visit, and the second ones were taken 6 months to 5 years after treatment.
Antigen preparation.
Borrelia strains, B. burgdorferi sensu stricto VS215, B. garinii VS102,
B. afzelii VS461, and B. valaisiana VS116 were
used for antigen preparation (32, 44). All strains were
isolated from ticks (I. ricinus) (33).
Spirochetes were cultured in BSK II medium (Sigma, St. Louis, Mo.).
During the late logarithmic phase of growth, the culture was
centrifuged at 14,000 × g for 15 min and washed twice
in phosphate-buffered saline (pH 7.2) to which MgCl2 (0.05 M) was added. The protein concentration of the suspension was
determined by the biuret method and was adjusted to 1 mg/ml in
distilled water. Washed Borrelia cells were stored at
20°C until use (34). The isolates used in this study
were all low-passage strains. Prior to Western blotting, all antigen preparations were adjusted to contain equal amounts of p41, which is
known to be present in rather constant amounts in all strains (16,
50) and which was quantified by serial dilution by Coomassie blue-stained immunoblotting and a densitometry analysis program.
Electrophoresis and immunoblotting.
Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and Western blotting were
performed by standard procedures (33). Briefly, samples were
heated for 5 min at 95°C before undergoing electrophoresis on a
polyacrylamide gel at 12.5% (constant voltage, 170 V). After
electrophoresis the proteins were transferred to a polyvinylidene
difluoride membrane and were cut into strips.
Before use, the strips were blocked for 1 h at 37°C with
Tris-buffered saline (TBS; pH 7.2) with 5% gelatin and were washed three times for 5 min each time with washing buffer (W-buffer; TBS with
0.1% gelatin and 0.05% Tween 20) at room temperature. Each step of
this procedure was performed at room temperature. The four antigen
strips were incubated for 2 h with patient serum diluted 1/500 in
D-buffer (TBS with 1% gelatin and 0.05% Tween 20). The strips were
washed three times for 5 min each time with W-buffer. After the
washing, rabbit anti-human IgG conjugated to alkaline phosphatase
diluted 1/1,000 in D-buffer was added. At the end of the second 2-h
incubation, two washes were done with W-buffer and one was done with
TBS. The bound conjugate was visualized by addition of the chromogenic
substrate 5-bromo-4-chloro-3-indolylphosphate-Nitro Blue Tetrazolium
(Kirkegaard & Perry Laboratories). The reaction was stopped 10 to 15 min later by two rinses in distilled water. Incubations were always
performed with all the strips of each antigen in the same well.
Characterization of protein bands.
Reproducibility was
confirmed by repeat probing of the immunoblot strips from different
gels with four serum samples preferentially reactive with each species.
In all strains the 39-kDa protein could be clearly differentiated from
the flagellin (41 kDa), the 30-kDa protein could be differentiated from
OspA, and the 58-kDa protein could be differentiated from the 60-kDa protein.
The blots were analyzed visually by one person, and the interpretation
was confirmed independently by an other one. Since
only minor
divergences were observed for the typing of the serological
reactions
between the two readers, we used the classification
of one reader only.
For comparison between the four strips, scores
(0 to 3 points) were
allocated depending on the presence and intensity
of the reaction to 19 proteins of
Borrelia: the 93-kDa (p100),
75-kDa, 66-kDa,
60-kDa, 58-kDa, 54- to 56-kDa, 45-kDa, 41-kDa
(flagellin), p39, 36-kDa,
OspA, 30-kDa, OspD, OspC, 20-kDa, 18-kDa,
16-kDa, 14-kDa, and 12-kDa
proteins. Some of these proteins were
identified in the four
Borrelia species with monoclonal antibodies:
LA 114 Zs7
(93-kDa protein) sl60 (60-kDa protein), H9724 (flagellin),
LA 112 Zs7
(39-kDa protein), and LA 22 2B8 (OspC) (kindly provided
by
A. G. Barbour, University of California, Irvine; R. Wallich,
Ruprecht-Karls-Universität, Heidelberg, Germany; and B. Wilske,
Max von Pettenkofer Institut, Munich, Germany). OspA was
identified
with two different monoclonal antibodies, H5332 (reactive
with
VS215, VS102, and VS461) and A116k (reactive with
B. valaisiana).
A report characterizing the A116k monoclonal antibody
is in preparation.
The other proteins were identified in the four
Borrelia species
by specific serum reactivities and
Molecular Analysis software
(Bio-Rad, Hercules, Calif.) (see Fig.
1 and
Table
1).
Determination of predominant reactivity for each species.
To
determine the preferential reactivities of the sera, a detailed
analysis was performed. Five of 13 proteins with a discriminative potential (the 12-kDa, 16-kDa, 18-kDa, OspA and 66-kDa proteins) were
selected and were used in a rapid first-step scoring procedure (method
I). A total score for these five proteins that was greater by two
points for one individual species compared with the scores for the
other species was considered as preferential reactivity. If
preferential reactivity could not be found, the scores for all 19 protein bands were taken into account (method II). A total score that
was three points greater for one individual species compared with the
scores for the other species was considered a preferential reactivity.
The differential number of scored points necessary to define this
preferential reactivity to one particular species was established on
the basis of a previous statistical study (32).
Comparison of immunoreactivity with genotypic detection.
Oligonucleotide primers that recognize the OspA sequences of most
B. burgdorferi strains (11) were used to amplify
DNA by PCR for patients for whom there was a clinical suspicion of Lyme arthritis. The presence of B. burgdorferi sensu lato DNA in
synovial fluid (n = 15) and urine (n = 1) samples was shown by agarose gel analysis. The specificities of
the PCR amplicons were controlled by colorimetric solid-phase capture
hybridization assay (28). Stored aliquots of each
PCR-positive synovial fluid or urine sample were retrospectively
analyzed with species-specific primers to type the infecting strains by
PCR. (11). Without knowing the results of the PCR, sera from
these patients were analyzed and the results were interpreted independently.
 |
RESULTS |
Characterization of serological responses.
In order to
determine the preferential reactivities of sera from patients with
neuroborreliosis (n = 31), ACA (n = 31), and Lyme arthritis (n = 34), the bands for
following proteins were scored and analyzed on four species-specific
immunoblots: the 93-kDa (p100), 75-kDa, 66-kDa, 60-kDa, 58-kDa, 54- to
56-kDa, 45-kDa, 41-kDa (flagellin), p39, 36-kDa, OspA, 30-kDa, OspD,
OspC, 20-kDa, 18-kDa, 16-kDa, 14-kDa, and 12-kDa proteins (Fig.
1; Table 1).

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 1.
Example of an immunoblot with a predominant score for
B. afzelii. Immunoblots (IgG) were done with the serum from
a patient with ACA. B.b.ss., B. burgdorferi sensu
stricto VS215; B.a., B. afzelii VS461; B.g., B. garinii VS102; B.v., B. valaisiana VS116. Boldface
indicates the five discriminative proteins used in method I.
|
|
When the specimens were grouped by their preferential reactivity to
each of the four species, only a few bands appeared to
have
discriminative potential. Among the sera with a preferential
reactivity
to
B. burgdorferi sensu stricto (
n = 23),
the 12-kDa,
16-kDa, OspC, 58-kDa, and 66-kDa antigen bands were found
to have
a higher discriminative power with
B. burgdorferi
sensu stricto
than with the other species. Sera with a preferential
reactivity
to
B. garinii (
n = 17) had
greater reactivities to the 16-kDa,
18-kDa, 20-kDa, OspC, OspD, 30-kDa,
OspA, 45-kDa, and 60-kDa antigen
bands. Sera with a preferential
reactivity to
B. afzelii (
n =
43) had
greater reactivities to the 12-kDa, 14-kDa, 16-kDa, 18-kDa,
OspC, and
45-kDa antigen bands. Among sera with a preferential
reactivity to
B. valaisiana (
n = 4), the reactivities to
the OspA,
45-kDa, and 66-kDa antigen bands were greater. The 12-kDa,
14-kDa,
16-kDa, 18-kDa, 20-kDa, OspC, OspD, 30-kDa, OspA, 45-kDa,
58-kDa,
60-kDa, and 66-kDa proteins had discriminative potential for
the
four species. On the basis of these results, the five proteins
with
the best discriminative potential (the 12-kDa, 16-kDa, 18-kDa,
OspA,
and 66-kDa proteins) were used in a rapid first-step procedure
to
determine the preferential reactivities of sera to the four
species
(Fig.
2A to D). If this procedure was not
discriminative,
the second step was then used and the results were
determined
on the basis of the scores for all 19 proteins.

View larger version (0K):
[in this window]
[in a new window]
|
FIG. 2.
Mean score of specific reactivity to different
Borrelia species. (A) Specific reactivity to B. burgdorferi sensu stricto (n = 23). (B) Specific
reactivity to B. garinii (n = 17). (C)
Specific reactivity to B. afzelii (n = 43).
(D) Specific reactivity to B. valaisiana (n = 4).
, B. burgdorferi sensu stricto; , B. garinii; , B. afzelii; , B. valaisiana.
|
|
Among the sera from patients with neuroborreliosis, 18 serum samples
had a preferential reactivity to one species after the
first step; the
results for 16 of them were confirmed by the second
step. For two
samples the total score was not greater by three
points. Among the sera
from patients with ACA and Lyme arthritis,
21 and 19 serum samples,
respectively, had a preferential reactivity
to one species after the
first step. The results for 19 and 17
of the samples respectively, were
confirmed by the second step.
For the four remaining serum samples the
total score was not greater
by three points for one species than for
the others. The percentages
of serum samples with preferential
reactivity to a particular
species are shown in Table
2. The percentages of serum samples
with
a preferential reactivity by the combined method were 90%
for patients
with neuroborreliosis (28 of 31), 94% for patients
with ACA (29 of
31), and 94% for patients with Lyme arthritis
(32 of 34). Of the three
serum samples from patients with neuroborreliosis
with undetermined
reactivities, one was from a patient with an
early infection and had a
weak reaction for IgG. We suspect a
mixed infection for another sample,
as the total scores for reactivity
to the 19 bands were clearly higher
with the
B. garinii and
B. afzelii
species-specific immunoblots than those with the
B. valaisiana and
B. burgdorferi sensu stricto
species-specific immunoblots.
Of the two serum samples from patients
with Lyme arthritis and
inconclusive reactivities to a particular
genospecies, one seemed
to be from a patient with a mixed infection.
The total scores
for the five specific bands were much higher with the
B. burgdorferi sensu stricto and
B. afzelii
species-specific immunoblots than
with the
B. garinii and
B. valaisiana species-specific immunoblots.
Two protein bands presented a preferential reactivity to one specific
species, regardless of the clinical symptoms. The 14-kDa
protein of
B. afzelii and the 58-kDa protein of
B. burgdorferi sensu stricto had higher
reactivities.
Preferential serological reactivities of sera from patients with
different clinical symptoms.
The percentages of serum samples from
each patient group showing a preferential reactivity to each species
are presented in Table 3. Reactivities of
sera from patients with neuroborreliosis were higher with the B. garinii-specific immunoblot (52%) than with those specific for
other species (6 to 22%). The reactivities of sera from patients with
ACA were predominant with the B. afzelii-specific immunoblot
(84%). The reactivities of sera from patients with Lyme arthritis were
higher with the B. burgdorferi sensu stricto-specific immunoblot (62%) and with the B. afzelii-specific
immunoblot (29%). Three serum samples from patients with
neuroborreliosis and one serum sample from a patient with Lyme
arthritis had preferential reactivities to B. valaisiana-specific immunoblot.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Percentage of serum samples per disease group showing
preferential reactivity for individual species by methods I and II
|
|
Persistence of reactivity to species-specific immunoblot.
The
persistence of the predominant reactivity after treatment with
antibiotics was evaluated by comparing sequential serum samples from
nine patients. Two paired serum samples from patients with
neuroborreliosis were analyzed. Both serum samples from one of them had
a preferential reactivity to B. valaisiana-specific immunoblot. For the other patient, the reactivity of the first serum
sample was inconclusive and the second serum sample had a preferential
reactivity to B. afzelii-specific immunoblot. A decreasing
IgG antibody response was observed for both of these patients. Six
pairs of serum samples from patients with ACA were analyzed. For both
serum samples from five of the patients, the sera had a preferential
reactivity to B. afzelii-specific immunoblot and the second
serum sample had a decreased immune response. The second serum sample
from one of the patients had a preferential reactivity only to B. burgdorferi sensu stricto-specific immunoblot, although a decrease
in the immune response was observed. One pair of serum samples from a
patient with Lyme arthritis was analyzed. Both serum samples had
preferential reactivity to B. burgdorferi sensu
stricto-specific immunoblot, with an increased immune response for the
second serum sample (obtained 3.5 years later).
Immunoblot reactivity compared with genomic detection.
PCR
with synovial and urine samples detected five B. burgdorferi
sensu stricto isolates one B. garinii isolate, nine B. afzelii isolates, and one untypeable Borrelia isolate.
Preferential reactivities were observed for serum samples from these
patients by immunoblotting (to B. burgdorferi sensu stricto
for 3 serum samples and to B. afzelii for 13 serum samples).
The results of these two methods, performed independently, agreed with
each other for samples from 11 patients (69%) (two samples had
preferential reactivity to B. burgdorferi sensu stricto and
nine samples had preferential reactivity to B. afzelii). One
sample had preferential reactivity to B. burgdorferi sensu
stricto by immunoblotting but could not be amplified with any
species-specific primers. One serum sample had a preferential
reactivity to B. afzelii by immunoblotting although the
results of PCR with urine from this patient indicated an infection with
B. garinii. Only three discrepancies were found. For two
samples the strain detected in the synovial fluid was B. afzelii, whereas the IgG immunoblots presented a preferential reactivity to B. burgdorferi sensu stricto, and for the
third sample, B. burgdorferi sensu stricto was detected in
the synovial fluid by PCR, but the IgG immunoblot suggested a B. afzelii infection.
 |
DISCUSSION |
Our four species-specific immunoblots allowed us to observe
predominant serum antibody reactivity to one Borrelia
species in the majority of serum samples from patients with chronic LB (90% for patients with neuroborreliosis [28 of 31], 94% for
patients with ACA [29 of 31], and 94% for patients with Lyme
arthritis [32 of 34]). The association of a given clinical
manifestation with a defined Borrelia species was confirmed
by these results. The predominant reactivity persisted long after
treatment of the disease. Indirect evidence suggested the involvement
of B. valaisiana in some chronic clinical manifestations.
Results of serological tests for LB may depend on the different
isolates causing infection and on the antigenic source, because
isolates from different species are rather heterogeneous (47,
48) and lead to differences in reactivities on Western blots
(3, 21, 26, 27, 30, 46, 49, 50). Moreover, as the infecting
species is geographic area specific (8), we studied the four
observed species in Switzerland and tested patients with LB from the
same area. Norman et al. (30) suggested that development,
optimization, and validation of immunoblotting criteria must be done
for each specific strain as different levels of reactivity to each
strain may occur. Therefore, we selected the best way to determine the
preferential reactivity to each Borrelia species.
Species-specific immunoblot analysis achieved by scoring individual
discriminative bands allowed determination of predominant reactivity
for a large percentage of serum samples. The preferential reactivity of
sera to one species was determined by a first-step analysis based on
the scores for five protein bands (the 12-kDa, 16-kDa, 18-kDa, OspA,
and 66-kDa proteins) with a high discriminative potential. Two of these
five proteins (the 18- and 66-kDa proteins) are recommended by the
Centers for Disease Control and Prevention for use in the confirmation
of positive serological tests. First, the 18-kDa protein has already been described by other investigators and is now considered a good
marker for LB (12, 22, 32, 38). Second, the 66-kDa protein
has been described as a heat shock protein with a high degree of
specificity for LB (7, 12, 25, 26). Analysis of isolates of
B. burgdorferi sensu lato obtained in North America and
Europe has demonstrated that OspA has antigenic variability and that
several distinct groups can be serologically defined (45,
47). However, there are controversial reports about its specificity in immunoblots (6, 10, 12, 20). The functions of
the 12- and 16-kDa antigens are not yet clear. When the rapid first-step scoring method was inconclusive, it was followed by a
second-step scoring method based on the total score for the 19 selected
proteins. In most instances, the analysis with 19 protein bands allowed
the confirmation and extension of the initial typing, leaving only a
few specimens with inconclusive reactivities. This two-step procedure
presented the advantage of a first rapid scoring method, with about
two-thirds of the serum samples having preferential reactivity at the
end of this step and 93% having preferential reactivity at the end of
the second-step. No divergence in preferential reactivities was
observed between the first-step approach and the second-step approach.
A preliminary blinded study comparing typing by immunoblotting with
genome detection in synovial fluids and urine from selected patients
showed agreement for 69% (11 of 16) of the samples. Only 4 of 16 samples showed discrepancies, and for the remaining sample no
comparison was possible. Among the four patients who provided the four
samples for which discrepancies were found, one had had frequent tick
bites over several years and so could have been in contact with several
B. burgdorferi sensu lato species. Only urine was available
from a second patient, and tests with the urine sample revealed the
presence of B. garinii, whereas the serological
interpretation was in favor of the presence of B. afzelii. A
mixed infection in this patient could also be envisaged. Serum from one
patient showed by IgG immunoblotting a preferential reactivity to
B. burgdorferi sensu stricto, but no amplification with
species-specific primers was possible.
The reproducibility of typing by immunoblotting was high with the sera
from a given patient. Among paired serum samples from seven patients,
the seven first serum samples with preferential reactivity to one of
the four species were shown to have the same reactivity as the second
serum samples in the pairs. Excluding the possibility of a risk of a
reinfection, the preferential reactivity of a serum sample may be
observed for several years. Although the possibility of reinfection
caused by the bites of separate ticks cannot be excluded, the presence
of several species in the lesions of EM and ACA patients may reflect
the occurrence of mixed infections in the local tick populations
(37). It was also shown that infection with multiple species
can persist in patients for a prolonged period (11). In our
study, the proportion of serum samples with undetermined reactivity was
10% for patients with neuroborreliosis, 6% for patients with ACA, and
6% for patients with Lyme arthritis. However, significantly higher
scores for reactivity to two of the four Borrelia species
were observed for two of the seven serum samples with inconclusive
reactivities, suggesting mixed infections. Sera from patients with ACA
clearly showed greater reactivity to B. afzelii, which
confirmed the results described by other investigators (2, 3, 13,
42). The reactivities of sera from patients with Lyme arthritis
were predominantly specific to B. burgdorferi sensu stricto
(62%) and B. afzelii (29%), which has also been confirmed
by other serological analyses (2, 3). However, a PCR
analysis performed with small numbers of synovial fluid samples in
Germany revealed no association between Lyme arthritis and B. burgdorferi sensu stricto (15, 43). In our study, we
also observed discrepant results between the serological study (62%
association with B. burgdorferi sensu stricto) and the PCR
analysis with a small number of samples (31% B. burgdorferi sensu stricto). We think that the selection of patients with Lyme arthritis on the basis of their PCR results is highly dependent on the
test characteristics and could have led to a biased prevalence of
Borrelia species. In addition, in the two studies (15,
43), large proportions of samples from patients with Lyme
arthritis (4 of 11 [36%] and 7 of 20 [35%], respectively) were
negative by PCR.
Our results lead us to confirm an association between B. garinii (52% of preferential reactivity) and neuroborreliosis,
although some investigators are opposed to such an association. The
good match described by Eiffert et al. (14) between the
distribution of B. burgdorferi sensu lato in ticks and CSF
from patients in the same area was interpreted to occur as a result of
the random selection of organisms detected in the examined ticks, but
it does not take into account the predominant occurrence of nymph bites
on humans (17). In Switzerland nymphs are mainly infected with B. afzelii (16a). The association between
neuroborreliosis and B. garinii in Europe has already been
described in other reports (2, 10, 11, 32, 42). The
percentage of association in this study was nevertheless lower than
that described by others. This may be explained by a falsely attributed
preferential reactivity to B. garinii in the absence of
B. valaisiana antigen. In this study B. valaisiana was tested by comparative immunoblotting for the first
time, and a pathogenic potential similar to that of B. garinii was suggested. Moreover B. garinii and B. valaisiana have both been demonstrated to have enzootic cycles in
avian hosts (18, 19, 29, 31). Furthermore, the phylogenetic
position of VS116 (B. valaisiana) has been described as
being closely related to that of B. garinii (5,
41). A preferential reactivity to B. valaisiana was
observed among three serum samples from patients with neuroborreliosis
and one patient with Lyme arthritis. These preliminary results provided
some additional clues as to the potential pathogenicity of B. valaisiana in humans. As recently reported (37),
B. valaisiana has been detected by PCR and restriction fragment length polymorphism analysis in skin biopsy specimens from two
EM patients, and mixed infections that included B. valaisiana were identified in both EM and ACA patients. The
clinical histories of the three patients who had neuroborreliosis and
who were potentially infected with B. valaisiana were
obtained. The three patients had partial facial palsy. One of them
presented with EM 14 days after a tick bite.
Conclusion.
Our scoring method with discriminative proteins on
immunoblots allows attribution of the serum reactivity of patients with chronic Lyme borreliosis to one Borrelia species for most
samples. Our results suggest an organotropism of Borrelia
species and provide some evidence of the pathogenic potential of
B. valaisiana in humans.
 |
ACKNOWLEDGMENTS |
This work was supported by the Foundation for Research and
Development from the Institut Central des Hôpitaux Valaisans and the Swiss Foundation for Scientific Research (grant 32.52739.97).
We thank A. F. Rodriguez and S. Bochuz for excellent technical
assistance and A. G. Barbour, B. Wilske, and R. Wallich for providing monoclonal antibodies.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Maladies
Infectieuses et Immunologie, Institut Central des Hôpitaux
Valaisans, Av. Grand-Champsec, CH-1950 Sion, Switzerland. Phone: 41 27 603 47 90. Fax: 41 27 603 48 93. E-mail:
olivier.peter{at}ichv.vsnet.ch.
 |
REFERENCES |
| 1.
|
Altpeter, E. S., and C. Meier.
1992.
Epidemiologische Aspekte der neurologischen Komplikationen der Lyme-Borreliose in der Schweiz.
Schweiz. Med. Wochenschr.
122:22-26[Medline].
|
| 2.
|
Anthonissen, F. M.,
M. De Kesel,
P. P. Hoet, and G. H. Bigaignon.
1994.
Evidence for the involvement of different genospecies of Borrelia in the clinical outcome of Lyme disease in Belgium.
Res. Microbiol.
145:327-331[Medline].
|
| 3.
|
Assous, M. V.,
D. Postic,
G. Paul,
P. Nevot, and G. Baranton.
1993.
Western blot analysis of sera from Lyme borreliosis patients according to the genomic species of the Borrelia strains used as antigens.
Eur. J. Clin. Microbiol. Infect. Dis.
12:261-268[Medline].
|
| 4.
|
Baranton, G.,
D. Postic,
I. Saint-Girons,
P. Boerlin,
J. C. Piffaretti,
M. Assous, and P. A. D. Grimont.
1992.
Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis.
Int. J. Syst. Bacteriol.
42:378-383[Abstract/Free Full Text].
|
| 5.
|
Bernasconi, M. V.,
C. Valsangiacomo,
T. Balmelli,
O. Péter, and J. C. Piffaretti.
1997.
Tick zoonoses in the southern part of Switzerland (Canton Ticino): occurrence of Borrelia burgdorferi sensu lato and Rickettsia sp.
Eur. J. Epidemiol.
13:209-215[Medline].
|
| 6.
|
Bruckbauer, H. R.,
V. Preac-Mursic,
R. Fuchs, and B. Wilske.
1992.
Cross-reactive proteins of Borrelia burgdorferi.
Eur. J. Clin. Microbiol. Infect Dis.
11:224-232[Medline].
|
| 7.
|
Bunikis, J.,
C. J. Luke,
E. Bunikiene,
S. Bergstrom, and A. G. Barbour.
1998.
A surface-exposed region of a novel outer membrane protein (P66) of Borrelia spp. is variable in size and sequence.
J. Bacteriol.
180:1618-1623[Abstract/Free Full Text].
|
| 8.
|
Bunikis, J.,
B. Olsen,
G. Westman, and S. Bergstrom.
1995.
Variable serum immunoglobulin responses against different Borrelia burgdorferi sensu lato species in a population at risk for and patients with Lyme disease.
J. Clin. Microbiol.
33:1473-1478[Abstract].
|
| 9.
|
Canica, M. M.,
F. Nato,
L. du Merle,
J. C. Mazie,
G. Baranton, and D. Postic.
1993.
Monoclonal antibodies for identification of Borrelia afzelii sp. nov. associated with late cutaneous manifestations of Lyme borreliosis.
Scand. J. Infect. Dis.
25:441-448[Medline].
|
| 10.
|
Cinco, M.,
R. Murgia,
M. Ruscio, and B. Andriolo.
1996.
IgM and IgG significant reactivity to Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii among Italian patients affected by Lyme arthritis or neuroborreliosis.
FEMS. Immunol. Med. Microbiol.
14:159-166[Medline].
|
| 11.
|
Demaerschalck, I.,
A. B. Messaoud,
M. de Kesel,
B. Hoyois,
Y. Lobet,
P. Hoet,
G. Bigaignon,
A. Bollen, and E. Godfroid.
1995.
Simultaneous presence of different Borrelia burgdorferi genospecies in biological fluids of Lyme disease patients.
J. Clin. Microbiol.
33:602-608[Abstract].
|
| 12.
|
Dressler, F.,
J. A. Whalen,
B. N. Reinhardt, and A. C. Steere.
1993.
Western blotting in the serodiagnosis of Lyme disease.
J. Infect. Dis.
167:392-400[Medline].
|
| 13.
|
Dunand, V.,
A. G. Bretz,
A. Suard,
G. Praz,
E. Dayer, and O. Péter.
1998.
Acrodermatitis chronica atrophicans and serologic confirmation of infection due to Borrelia afzelii and/or Borrelia garinii by immunoblot.
Clin. Microbiol. Infect.
4:159-163.
[Medline] |
| 14.
|
Eiffert, H.,
A. Ohlenbusch,
H.-J. Christen,
R. Thompsen,
A. Spielman, and F.-R. Matuschka.
1995.
Nondifferentiation between Lyme disease spirochetes from vector ticks and human cerebrospinal fluid.
J. Infect. Dis.
171:476-479[Medline].
|
| 15.
|
Eiffert, H.,
A. Karsten,
R. Thompsen, and H.-J. Christen.
1998.
Characterization of Borrelia burgdorferi strains in Lyme arthritis.
Scand. J. Infect. Dis.
30:265-268[Medline].
|
| 16.
|
Engstrom, S. M.,
E. Shoop, and R. C. Johnson.
1995.
Immunoblot interpretation criteria for serodiagnosis of early Lyme disease.
J. Clin. Microbiol.
33:419-427[Abstract].
|
| 16a.
| Gern, L. Personal communication.
|
| 17.
|
Gray, J. S.,
O. Kahl,
J. N. Robertson,
M. Daniel,
A. Estrada-Pena,
G. Gettinby,
T. G. Jaenson,
P. Jensen,
F. Jongejan,
F. Korenberg,
K. Kurtenbach, and P. Zeman.
1998.
Lyme borreliosis habitat assessment.
Zentralbl. Bakteriol.
287:211-228[Medline].
|
| 18.
|
Humair, P. F.,
D. Postic,
R. Wallich, and L. Gern.
1998.
An avian reservoir (Turdus merula) of the Lyme borreliosis spirochetes.
Zentbl. Bakteriol. Parasitenkd. Infektkrankh. Hyg. Abt. 1 Orig.
287:521-538.
|
| 19.
|
Isogai, E.,
S. Tanaka,
I. S. Braga III,
C. Itakura,
H. Isogai,
K. Kimura, and N. Fujii.
1994.
Experimental Borrelia garinii infection of Japanese quail.
Infect. Immun.
62:3580-3582[Abstract/Free Full Text].
|
| 20.
|
Kalish, R. A.,
J. M. Leong, and A. C. Steere.
1993.
Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi.
Infect. Immun.
61:2774-2779[Abstract/Free Full Text].
|
| 21.
|
Karlsson, M.
1991.
Antibody response against autologous and heterologous isolates of Borrelia burgdorferi in four patients with Lyme neuroborreliosis.
Eur. J. Clin. Microbiol. Infect. Dis.
10:742-745[Medline].
|
| 22.
|
Karlsson, M.,
I. Mollegard,
G. Stiernstedt, and B. Wretlind.
1989.
Comparison of Western blot and enzyme-linked immunosorbent assay for diagnosis of Lyme borreliosis.
Eur. J. Clin. Microbiol. Infect. Dis.
8:871-877[Medline].
|
| 23.
|
Kirstein, F.,
S. Rijpkema,
M. Molkenboer, and J. S. Gray.
1997.
The distribution and prevalence of B. burgdorferi genomospecies in Ixodes ricinus ticks in Ireland.
Eur. J. Epidemiol.
13:67-72[Medline].
|
| 24.
|
Le Fleche, A.,
D. Postic,
K. Girardet,
O. Péter, and G. Baranton.
1997.
Characterization of Borrelia lusitaniae sp. nov. by 16S ribosomal DNA.
Int. J. Syst. Bacteriol.
47:921-925[Abstract/Free Full Text].
|
| 25.
|
Luft, B. J.,
P. D. Gorevic,
W. Jiang,
P. Munoz, and R. J. Dattwyler.
1991.
Immunologic and structural characterization of the dominant 66- to 73-kDa antigens of Borrelia burgdorferi.
J. Immunol.
146:2776-2782[Abstract].
|
| 26.
|
Ma, B.,
B. Christen,
D. Leung, and C. Vigo-Pelfrey.
1992.
Serodiagnosis of Lyme borreliosis by Western immunoblot: reactivity of various significant antibodies against Borrelia burgdorferi.
J. Clin. Microbiol.
30:370-376[Abstract/Free Full Text].
|
| 27.
|
Magnarelli, L. A.,
J. F. Anderson,
R. C. Johnson,
R. B. Nadelman, and G. P. Wormser.
1994.
Comparison of different strains of Borrelia burgdorferi sensu lato used as antigens in enzyme-linked immunosorbent assays.
J. Clin. Microbiol.
32:1154-1158[Abstract/Free Full Text].
|
| 28.
|
Mansy, F.,
B. Hoyois,
M. J. de Vos,
A. van Elsen,
A. Bollen, and E. Godfroid.
1996.
Colorimetric solid-phase capture hybridization assay for detection of amplified Borrelia burgdorferi DNA.
BioTechniques
21:122-125[Medline].
|
| 29.
|
Nakao, M.,
K. Miyamoto, and M. Fukunaga.
1994.
Lyme disease spirochetes in Japan: enzootic transmission cycles in birds, rodents, and Ixodes persulcatus ticks.
J. Infect. Dis.
170:878-882[Medline].
|
| 30.
|
Norman, G. L.,
J. M. Antig,
G. Bigaignon, and W. R. Hogrefe.
1996.
Serodiagnosis of Lyme borreliosis by Borrelia burgdorferi sensu stricto, B. garinii, and B. afzelii Western blots (immunoblots).
J. Clin. Microbiol.
34:1732-1738[Abstract].
|
| 31.
|
Olsen, B.,
T. G. Jaenson,
L. Noppa,
J. Bunikis, and S. Bergstrom.
1993.
A Lyme borreliosis cycle in seabirds and Ixodes uriae ticks.
Nature
362:340-342[Medline].
|
| 32.
|
Péter, O.,
A.-G. Bretz,
D. Postic, and E. Dayer.
1997.
Association of distinct species of Borrelia burgdorferi sensu lato with neuroborreliosis in Switzerland.
Clin. Microbiol. Infect.
3:423-431.
[Medline] |
| 33.
|
Péter, O., and A. G. Bretz.
1992.
Polymorphism of outer surface proteins of Borrelia burgdorferi as a tool for classification.
Zentbl. Bakteriol. Parasitenkd. Infektkrankh. Hyg. Abt. 1 Orig.
277:28-33.
|
| 34.
|
Péter, O.,
A. G. Bretz, and D. Bee.
1995.
Occurrence of different genospecies of Borrelia burgdorferi sensu lato in Ixodid ticks of Valais, Switzerland.
Eur. J. Epidemiol.
11:463-467[Medline].
|
| 35.
|
Postic, D.,
M. V. Assous,
P. A. Grimont, and G. Baranton.
1994.
Diversity of Borrelia burgdorferi sensu lato evidenced by restriction fragment length polymorphism of rrf (5S)-rrl (23S) intergenic spacer amplicons.
Int. J. Syst. Bacteriol.
44:743-752[Abstract/Free Full Text].
|
| 36.
|
Rijpkema, S. G.,
R. G. Herbes,
N. Verbeek-De Kruif, and J. F. Schellekens.
1996.
Detection of four species of Borrelia burgdorferi sensu lato in Ixodes ricinus ticks collected from roe deer (Capreolus capreolus) in The Netherlands.
Epidemiol. Infect.
117:563-566[Medline].
|
| 37.
|
Rijpkema, S. G. T.,
D. Tazelaar,
M. Molkenboer,
G. Noordhoek,
G. Plantinga,
L. Schouls, and J. Schellekens.
1997.
Detection of Borrelia afzelii, Borrelia burgdorferi sensu stricto, Borrelia garinii and group VS116 by PCR in skin biopsies of patients with erythema migrans and acrodermatitis chronica atrophicans.
Clin. Microbiol. Infect.
3:109-116.
[Medline] |
| 38.
|
Ryffel, K.,
O. Péter,
L. Binet, and E. Dayer.
1998.
Interpretation of immunoblots for Lyme borreliosis using a semiquantitative approach.
Clin. Microbiol. Infect.
4:205-212.
[Medline] |
| 39.
|
Saint Girons, I.,
L. Gern,
J. S. Gray,
E. C. Guy,
E. Korenberg,
P. A. Nuttall,
S. G. T. Rijpkema,
A. Schönberg,
G. Stanek, and D. Postic.
1998.
Identification of Borrelia burgdorferi sensu lato species in Europe.
Zentbl. Bakteriol. Parasitenkd. Infektkrankh. Hyg. Abt. 1 Orig.
287:190-195.
|
| 40.
|
Steere, A. C.
1989.
Lyme disease.
N. Engl. J. Med.
321:586-596[Abstract].
|
| 41.
|
Valsangiacomo, C.,
T. Balmelli, and J. C. Piffaretti.
1997.
A phylogenetic analysis of Borrelia burgdorferi sensu lato based on sequence information from the hbb gene, coding for a histone-like protein.
Int. J. Syst. Bacteriol.
47:1-10[Abstract/Free Full Text].
|
| 42.
|
van Dam, A. P.,
H. Kuiper,
K. Vos,
A. Widdjojokusumo,
B. M. de Jongh,
S. Spanjaard,
A. C. T. Ramselaar,
M. D. Kramer, and J. Dankert.
1993.
Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis.
Clin. Infect. Dis.
17:708-717[Medline].
|
| 43.
|
Vasiliu, V.,
P. Herzer,
D. Rossler,
G. Lehnert, and B. Wilske.
1998.
Heterogeneity of Borrelia burgdorferi sensu lato demonstrated by an ospA-type-specific PCR in synovial fluid from patients with Lyme arthritis.
Med. Microbiol. Immunol. (Berlin)
187:97-102[Medline].
|
| 44.
|
Wang, G.,
A. P. van Dam,
A. Le Flèche,
D. Postic,
O. Péter,
G. Baranton,
R. de Boer,
L. Spanjaard, and J. Dankert.
1997.
Genetic and phenotypic analysis of Borrelia valaisiana sp. nov. (Borrelia genomic groups VS116 and M19).
Int. J. Syst. Bacteriol.
47:926-932[Abstract/Free Full Text].
|
| 45.
|
Wilske, B.,
U. Busch,
H. Eiffert,
V. Fingerle,
H. W. Pfister,
D. Rössler, and V. Preac-Mursic.
1996.
Diversity of OspA and OspC among cerebrospinal fluid isolates of Borrelia burgdorferi sensu lato from patients with neuroborreliosis in Germany.
Med. Microbiol. Immunol. (Berlin)
184:195-201[Medline].
|
| 46.
|
Wilske, B.,
V. Fingerle,
V. Preac-Mursic,
S. Jauris-Heipke,
A. Hofmann,
H. Loy,
H. W. Pfister,
D. Rössler, and E. Soutschek.
1994.
Immunoblot using recombinant antigens derived from different genospecies of Borrelia burgdorferi sensu lato.
Med. Microbiol. Immunol. (Berlin)
183:43-59[Medline].
|
| 47.
|
Wilske, B.,
V. Preac-Mursic,
U. B. Göbel,
B. Graf,
S. Jauris,
E. Soutschek,
E. Schwab, and G. Zumstein.
1993.
An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis.
J. Clin. Microbiol.
31:340-350[Abstract/Free Full Text].
|
| 48.
|
Wilske, B.,
V. Preac-Mursic,
S. Jauris,
A. Hofmann,
I. Pradel,
E. Soutschek,
E. Schwab,
G. Will, and G. Wanner.
1993.
Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of Borrelia burgdorferi.
Infect. Immun.
61:2182-2191[Abstract/Free Full Text].
|
| 49.
|
Wilske, B.,
V. Preac-Mursic,
G. Schierz, and K. V. Busch.
1986.
Immunochemical and immunological analysis of European Borrelia burgdorferi strains.
Zentbl. Bakteriol Mikrobiol. Hyg. Reihe A
263:92-102.
|
| 50.
|
Zoller, L.,
S. Burkard, and H. Schafer.
1991.
Validity of Western immunoblot band patterns in the serodiagnosis of Lyme borreliosis.
J. Clin. Microbiol.
29:174-182[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, December 1999, p. 4086-4092, Vol. 37, No. 12
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kraiczy, P., Seling, A., Brissette, C. A., Rossmann, E., Hunfeld, K.-P., Bykowski, T., Burns, L. H., Troese, M. J., Cooley, A. E., Miller, J. C., Brade, V., Wallich, R., Casjens, S., Stevenson, B.
(2008). Borrelia burgdorferi Complement Regulator-Acquiring Surface Protein 2 (CspZ) as a Serological Marker of Human Lyme Disease. CVI
15: 484-491
[Abstract]
[Full Text]
-
Younsi, H., Sarih, M., Jouda, F., Godfroid, E., Gern, L., Bouattour, A., Baranton, G., Postic, D.
(2005). Characterization of Borrelia lusitaniae Isolates Collected in Tunisia and Morocco. J. Clin. Microbiol.
43: 1587-1593
[Abstract]
[Full Text]
-
Godfroid, E., Min Hu, C., Humair, P.-F., Bollen, A., Gern, L.
(2003). PCR-Reverse Line Blot Typing Method Underscores the Genomic Heterogeneity of Borrelia valaisiana Species and Suggests Its Potential Involvement in Lyme Disease. J. Clin. Microbiol.
41: 3690-3698
[Abstract]
[Full Text]
-
Ornstein, K., Ostberg, Y., Bunikis, J., Noppa, L., Berglund, J., Norrby, R., Bergstrom, S.
(2002). Differential Immune Response to the Variable Surface Loop Antigen of P66 of Borrelia burgdorferi Sensu Lato Species in Geographically Diverse Populations of Lyme Borreliosis Patients. CVI
9: 1382-1384
[Abstract]
[Full Text]
-
Panelius, J., Lahdenne, P., Saxen, H., Heikkila, T., Seppala, I.
(2001). Recombinant Flagellin A Proteins from Borrelia burgdorferi Sensu Stricto, B. afzelii, and B. garinii in Serodiagnosis of Lyme Borreliosis. J. Clin. Microbiol.
39: 4013-4019
[Abstract]
[Full Text]
-
Lin, T., Oliver, J. H. Jr., Gao, L., Kollars, T. M. Jr., Clark, K. L.
(2001). Genetic Heterogeneity of Borrelia burgdorferi Sensu Lato in the Southern United States Based on Restriction Fragment Length Polymorphism and Sequence Analysis. J. Clin. Microbiol.
39: 2500-2507
[Abstract]
[Full Text]
-
Bretz, A. G., Ryffel, K., Hutter, P., Dayer, E., Peter, O.
(2001). Specificities and Sensitivities of Four Monoclonal Antibodies for Typing of Borrelia burgdorferi Sensu Lato Isolates. CVI
8: 376-384
[Abstract]
[Full Text]
-
Escudero, R., Barral, M., Pérez, A., Vitutia, M. M., García-Pérez, A. L., Jiménez, S., Sellek, R. E., Anda, P.
(2000). Molecular and Pathogenic Characterization of Borrelia burgdorferi Sensu Lato Isolates from Spain. J. Clin. Microbiol.
38: 4026-4033
[Abstract]
[Full Text]